Article
Actionable mutations in muscle-invasive bladder cancer.
Current opinion in urology - 1 Sept 2013
Bambury Richard M, Rosenberg Jonathan E
Abstract excerpt
PURPOSE OF REVIEW: Thirty-five percent of bladder cancer patients either present with or develop muscle-invasive disease. The current standard of care for these patients is neoadjuvant chemotherapy followed by radical cystoprostatectomy or combined chemoradiotherapy. Despite these therapies, approximately 50% of patients will relapse after definitive locoregional treatment and eventually succumb to their disease....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.